Particles formed by polymeric adjuvants preferentially localize to the lymph node and elicit robust immunity.
References
Lynn, G.M. et al. Nat. Biotechnol. 33, 1201–1210 (2015).
Steinhagen, F., Kinjo, T., Bode, C. & Klinman, D.M. Vaccine 29, 3341–3355 (2011).
Vasilakos, J.P. & Tomai, M.A. Expert Rev. Vaccines 12, 809–819 (2013).
Kawai, T. & Akira, S. Immunity 34, 637–650 (2011).
Lizée, G. et al. Annu. Rev. Med. 64, 71–90 (2013).
Wu, T.Y. et al. Sci. Transl. Med. 6, 263ra160 (2014).
Hanson, M.C. et al. J. Clin. Invest. 125, 2532–2546 (2015).
Kopeček, J. & Kopečková, P. Adv. Drug Deliv. Rev. 62, 122–149 (2010).
Park, H. et al. J. Immunol. 190, 4103–4115 (2013).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Dane, E., Irvine, D. Big thinking for adjuvants. Nat Biotechnol 33, 1146–1148 (2015). https://doi.org/10.1038/nbt.3398
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.3398
- Springer Nature America, Inc.
This article is cited by
-
A nanoscale metal organic frameworks-based vaccine synergises with PD-1 blockade to potentiate anti-tumour immunity
Nature Communications (2020)